General Information of Drug (ID: DMHU8SJ)

Drug Name
MB07803 Drug Info
Synonyms
MB-07803; 882757-24-6; UNII-GG81XF45C2; MB 07803; GG81XF45C2; SCHEMBL14255484; DTXSID90236932; ACT04837; SB17400; DB05053; HY-16309; CS-0006389; Alanine, N,N'-((5-(2-amino-5-(2,2-dimethyl-1-oxopropyl)-4-thiazolyl)-2-furanyl)phosphinylidene)bis(2-methyl-, diethyl ester; n,n'-((5-(2-amino-5-(2,2-dimethyl-1-oxopropyl)-4-thiazolyl)-2-furanyl)phosphinylidene)bis(2-methylalanine) diethyl ester
Indication
Disease Entry ICD 11 Status REF
Type-2 diabetes 5A11 Phase 2 [1]
Cross-matching ID
PubChem CID
24770445
CAS Number
CAS 882757-24-6
TTD Drug ID
DMHU8SJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Managlinat dialanetil DMBYDNE Type-2 diabetes 5A11 Phase 2 [3]
4,6-Dichloro-1H-indole-2-carboxylic acid DM62XC3 Discovery agent N.A. Investigative [4]
4-(2-amino-1,3-thiazol-4-yl)phenol DMH5CAQ Discovery agent N.A. Investigative [5]
Fructose-6-Phosphate DMU5SAF Discovery agent N.A. Investigative [6]
1-(4-aminophenylsulfonyl)-3-(2-mercaptoethyl)urea DM4G0NH Discovery agent N.A. Investigative [7]
2,5-Anhydroglucitol-1,6-Biphosphate DMLDHMB Discovery agent N.A. Investigative [6]
1-(2-mercaptoethyl)-3-(m-tolylsulfonyl)urea DMIPAMW Discovery agent N.A. Investigative [7]
4-(4-(4-Nitrophenyl)thiazol-2-ylamino)phenol DMA9TCD Discovery agent N.A. Investigative [5]
3-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol DM8EH07 Discovery agent N.A. Investigative [5]
2-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol DMOYT8I Discovery agent N.A. Investigative [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fructose-1,6-bisphosphatase (FBP) TTWHDVK F16P1_HUMAN; F16P2_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT00458016) Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3 MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proc Natl Acad Sci U S A. 2005 May 31;102(22):7970-5.
4 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
5 A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase. Bioorg Med Chem. 2009 Jun 1;17(11):3916-22.
6 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7 Allosteric FBPase inhibitors gain 10(5) times in potency when simultaneously binding two neighboring AMP sites. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4708-12.